Abstract
Aims
Severe hypoglycemia has a significant deteriorating effect on quality of life of the individual and has been associated with increased mortality. The aim of this study was to investigate the mortality among people with type 1 and type 2 diabetes suffering from severe hypoglycemia in Denmark in the last two decades.
Methods
People diagnosed with type 1 (n = 44,033) and type 2 diabetes (n = 333,581) were extracted from the complete population of Denmark from 1996 to 2017 via ICD-10 diabetes codes and ATC diabetes medication codes. People suffering from severe hypoglycemia (type 1 diabetes n = 8808, type 2 diabetes n = 5605) as identified from ICD-10 codes were then matched 1:1 by year of birth, gender and year of diabetes diagnosis with those without severe hypoglycemia. Cox proportional hazards models were constructed to analyze the effect of severe hypoglycemia on mortality.
Results
For both people with type 1 (HR 1.11, CI 95% 1.06 to 1.17) and type 2 diabetes (HR 1.77, CI 95% 1.67 to 1.87) suffering from hypoglycemia, an increased mortality risk was observed, compared to people without severe hypoglycemia. An investigation of the death causes did not indicate an association between the severe hypoglycemic episodes and death.
Conclusion
In this study, severe hypoglycemic episodes increased the mortality risk for people with type 1 and type 2 diabetes. The risk was higher among people with type 2 diabetes. Whether severe hypoglycemia is a symptom of other underlying illnesses increasing mortality risk or a risk factor itself needs further investigation.
Similar content being viewed by others
References
Lachin JM, White NH, Hainsworth DP, Sun W, Cleary PA, Nathan DM (2015) Effect of intensive Diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes 64:631–642
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131):837–853
Bailey CJ, Day C (2008) Glycaemic memory. Br J Diabetes Vasc Dis 8:242–247
Gubitosi-Klug RA, Braffett BH, White NH et al (2017) Risk of severe hypoglycemia in type 1 diabetes over 30 years of follow-up in the DCCT/EDIC study. Diabetes Care 40:1010–1016
Zoungas S, Patel A, Chalmers J et al (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 363(15):1410–1418
Sejling A, Schouwenberg B, Faerch L, Thorsteinsson B, de Galan B, Pedersen-Bjergaard U (2015) Association between hypoglycaemia and impaired hypoglycaemia awareness and mortality in people with Type 1 diabetes mellitus. Diabet Med 33(1):77–83
American Diabetes Association Workgroup on Hypoglycemia (2005) Defining and reporting hypoglycemia in diabetes. Diabetes Care 28(5):1245–1249
Bonaventura A, Montecucco F, Dallegri F (2015) Update on strategies limiting iatrogenic hypoglycemia. Endocr Connect 4(3):R37–R45
Oyer DS (2013) The science of hypoglycemia in patients with diabetes. Curr Diabetes Rev 9:195–208
Morales J, Schneider D (2014) Hypoglycemia. Am J Med 127(10 Suppl):S17–24
Van Dalem J, Brouwers MCGJ, Stehouwer CDA et al (2016) Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ 354:1–8
Heller SR, Frier BM, Hersløv ML, Gundgaard J, Gough SCL (2016) Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources. Diabet Med 33(4):471–477
McCoy R, Van Houten H, Ziegenfuss J, Shah N, Wermers R, Smith S (2012) Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 35(9):1897–1901
Zaccardi F, Dhalwani NN, Webb DR, Davies MJ, Khunti K (2018) Global burden of hypoglycaemia-related mortality in 109 countries, from 2000 to 2014: an analysis of death certificates. Diabetologia 61(7):1592–1602
Tella SH, Rendell MS (2015) DPP-4 inhibitors: focus on safety. Expert Opin Drug Saf 14(1):127–140
Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA (2017) A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes, Obes Metab. 2017;19(2):216–27
Bonaventura A, Carbone S, Dixon DL, Abbate A, Montecucco F (2019) Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists. J Intern Med 286(1):16–31
Filippas-Ntekouan S, Filippatos TD, Elisaf MS (2018) SGLT2 inhibitors: are they safe? Postgrad Med 130(1):72–82
Marso SP, McGuire DK, Zinman B et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 377(8):723–732
Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-Järvinen H (2018) Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab 20(3):541–548
Schmidt M, Alba S, Schmidt J et al (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 7:449–490
Schmidt M, Pedersen L, Sørensen H (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29(8):541–549
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method for classifying prognostic comorbidity in longitudinal studies. J Chron Dis 40:373–384
Ilic M, Ilic I (2016) Epidemiology of pancreatic cancer. World J Gastroenterol 22(44):9694–9705
Kittah NE, Vella A (2017) Pathogenesis and management of hypoglycemia. Eur J Endocrinol 177(1):R37–R47
Quaresma M, Coleman MP, Rachet B (2015) 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. Lancet 385(9974):1206–1218
Cryer PE (2017) Individualized glycemic goals and an expanded classification of severe hypoglycemia in diabetes. Diabetes Care 40(12):1641–1643
Kakei M, Tsujimoto T, Noto H et al (2013) Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients. Diabetes Care 37(1):217–225
Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR (2015) Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 3(1):43–51
Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429–42
Lynge E, Sandegaard JL, Rebolj M (2011) The Danish national patient register. Scand J Public Health 39(7):30–33
Mosbech J, Jørgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen T (1995) The national patient registry. Evaluation of data quality. Ugeskr Laeger 157(26):3741–3745
Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 156(1):8–10
Bonaventura A, Gallo F, Carbone F et al (2017) Low serum C-reactive protein levels predict 90-day mortality in hypoglycaemic patients. Diabetes Metab 43(6):554–556
Bonaventura A, Gallo F, Carbone F et al (2018) Levels of serum uric acid at admission for hypoglycaemia predict 1-year mortality. Acta Diabetol. 55(4):323–330
Funding
This study was not funded.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Author Vestergaard has received unrestricted Grants from MSD and Servier and travel grants from Amgen, Eli Lilly, Novartis, Sanofi Aventis and Servier. Auther Dethlefsen is employed at Novo Nordisk A/S. Author Jensen is former employee at Novo Nordisk A/S and holds shares in the company.
Ethical approval
All data was handled in accordance with the General Data Protection Regulation (EU) 2016/679. No ethical approval is necessary in Denmark when handling registry data only.
Informed consent
For this study, formal consent was not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jensen, M.H., Dethlefsen, C., Hejlesen, O. et al. Association of severe hypoglycemia with mortality for people with diabetes mellitus during a 20-year follow-up in Denmark: a cohort study. Acta Diabetol 57, 549–558 (2020). https://doi.org/10.1007/s00592-019-01447-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-019-01447-x